Detección inesperada de carcinoma ductal infiltrante no palpable de mama con 99mTc-HYNIC-TOC (Tektrotyd®) / Unexpected detection of non-palpable breast ductal invasive carcinoma with 99mTc-HYNIC-TOC (Tektrotyd®)

No disponible

Captación de 18F-florbetapir en un hemangioma intraóseo visualizado en una PET/TC cerebral / 18F-florbetapir uptake in a primary intraosseous haemangioma displayed in a cerebral PET/CT

No disponible

Coexistencia de metástasis óseas por cáncer gástrico y osteopoiquilia diagnosticadas mediante gammagrafía ósea y 18F-FDG PET/TC / Gastric cancer bone metastases together with osteopoikilosis diagnosed using bone scintigraphy and 18F-FDG PET/CT

La coexistencia de distintas alteraciones óseas en un mismo paciente es un hallazgo que plantea un diagnóstico diferencial complejo. Presentamos el caso de una paciente en estudio por una lesión renal, que en la radiografía convencional y en la TC presentó múltiples lesiones esclerosas en columna y extremidades, que se valoraron mediante gammagrafía ósea con 99mTc-HDP y 18F-FDG PET/TC, obteniéndose el diagnóstico definitivo mediante la anatomía patológica de coexistencia de metástasis óseas por cáncer gástrico y osteopoiquilia (OP). Entre las técnicas de imagen realizadas, la gammagrafía aportó el mayor rendimiento diagnóstico por su capacidad de discriminación entre enfermedad ósea benigna y metastásica (AU)

The coexistence of different bone diseases in the same patient involves a complex differential diagnosis. A patient is presented who was studied due to a renal mass that showed many sclerotic lesions in spine and limbs in conventional radiology and CT. These lesions were evaluated with 99mTC-HDP bone scintigraphy and 18F-FDG PET/CT, which helped to obtain the definitive pathological diagnosis of osteopoikilosis (OP) co-existing with gastric cancer bone metastases. Of the different imaging scans performed, bone scintigraphy was particularly relevant due to its ability to discriminate between benign and metastatic bone disease (AU)

Más allá del nomograma de Briganti: individualización de la linfadenectomía utilizando la biopsia selectiva del ganglio centinela durante la prostatectomía radical por cáncer de próstata / Beyond the Briganti nomogram: Individualisation of lymphadenectomy using selective sentinel node biopsy during radical prostatectomy for prostate cancer

Objetivo: Validar la técnica de biopsia selectiva de ganglio centinela en el diagnóstico y estadificación del cáncer de próstata de riesgo intermedio y alto mediante comparación con la linfadenectomía extendida convencional (eLFD) en un estudio prospectivo longitudinal y comparativo. Métodos: Hemos aplicado la técnica a 45 pacientes. Previa inyección intraprostática de 99mTc-nanocoloide y SPECT-TC preoperatoria, se han extraído los ganglios centinela guiados con gammacámara portátil Sentinella® y sonda detectora de rayos gamma laparoscópica. Se completó la eLFD para establecer el valor predictivo negativo de la técnica. Resultados: La SPECT-TC mostró depósitos del radiotrazador fuera del territorio de la eLFD en el 73% de los pacientes y la gammasonda laparoscópica en el 60%. La media de focos activos por paciente en la SPECT-TC fue de 4,3 y con gammasonda laparoscópica de 3,2. La media de ganglios linfáticos centinelas extraídos fue 4,3 (0-14), el 26% fuera del territorio de la eLFD. En 10 pacientes (22%) se encontraron ganglios metastásicos, 6/40 (15%) cuando la prostatectomía fue el tratamiento primario. En todos los casos con ganglios metastásicos hubo, al menos, un ganglio centinela positivo. Se encontraron ganglios centinela metastásicos fuera del territorio de la eLFD en 3/10 pacientes (30%). La sensibilidad fue del 100%, la especificidad del 94,73%, el valor predictivo positivo del 81,81% y el valor predictivo negativo del 100%. Conclusión: La biopsia selectiva del ganglio centinela es superior a la eLFD en el diagnóstico de afectación ganglionar, y puede evitar la eLFD cuando no se encuentren ganglios centinela metastásicos (85%), con las consecuentes ventajas funcionales

Objective: To validate the technique of selective sentinel node biopsy for diagnosing and staging intermediate to high-risk prostate cancer by comparing the technique with conventional extended lymphadenectomy (eLFD) in a prospective, longitudinal comparative study. Methods: We applied the technique to 45 patients. After an intraprostatic injection of 99mTc-nanocolloid and preoperative single-photon emission computed tomography (SPECT/CT), we extracted the sentinel lymph nodes, guided by a portable Sentinella® gamma camera and a laparoscopic gamma-ray detection probe. The eLFD was completed to establish the negative predictive value of the technique. Results: SPECT/CT showed radiotracer deposits outside the eLFD territory in 73% of the patients and the laparoscopic gamma probe in 60%. The mean number of active foci per patient was 4.3 in the SPECT/CT and 3.2 in the laparoscopic gamma probe. The mean number of extracted sentinel lymph nodes was 4.3 (0-14), with 26% outside the eLFD territory. The lymph nodes were metastatic in 10 patients (22%), 6/40 (15%) when the prostatectomy was the primary treatment. In all cases with metastatic lymph nodes, there was at least one positive sentinel node. Metastatic sentinel lymph nodes were found outside the eLFD territory in 3/10 patients (30%). The sensitivity was 100%, the specificity was 94.73%, the positive predictive value was 81.81%, and the negative predictive value was 100%. Conclusion: Selective sentinel node biopsy is superior to eLFD for diagnosing lymph node involvement and can avoid eLFD when metastatic sentinel lymph nodes are not found (85%), with the consequent functional advantages

Beyond the Briganti nomogram: Individualisation of lymphadenectomy using selective sentinel node biopsy during radical prostatectomy for prostate cancer. / Más allá del nomograma de Briganti: individualización de la linfadenectomía utilizando la biopsia selectiva del ganglio centinela durante la prostatectomía radical por cáncer de próstata.

OBJECTIVE: To validate the technique of selective sentinel node biopsy for diagnosing and staging intermediate to high-risk prostate cancer by comparing the technique with conventional extended lymphadenectomy (eLFD) in a prospective, longitudinal comparative study. METHODS: We applied the technique to 45 patients. After an intraprostatic injection of 99mTc-nanocolloid and preoperative single-photon emission computed tomography (SPECT/CT), we extracted the sentinel lymph nodes, guided by a portable Sentinella® gamma camera and a laparoscopic gamma-ray detection probe. The eLFD was completed to establish the negative predictive value of the technique. RESULTS: SPECT/CT showed radiotracer deposits outside the eLFD territory in 73% of the patients and the laparoscopic gamma probe in 60%. The mean number of active foci per patient was 4.3 in the SPECT/CT and 3.2 in the laparoscopic gamma probe. The mean number of extracted sentinel lymph nodes was 4.3 (0-14), with 26% outside the eLFD territory. The lymph nodes were metastatic in 10 patients (22%), 6/40 (15%) when the prostatectomy was the primary treatment. In all cases with metastatic lymph nodes, there was at least one positive sentinel node. Metastatic sentinel lymph nodes were found outside the eLFD territory in 3/10 patients (30%). The sensitivity was 100%, the specificity was 94.73%, the positive predictive value was 81.81%, and the negative predictive value was 100%. CONCLUSION: Selective sentinel node biopsy is superior to eLFD for diagnosing lymph node involvement and can avoid eLFD when metastatic sentinel lymph nodes are not found (85%), with the consequent functional advantages.

Gastric cancer bone metastases together with osteopoikilosis diagnosed using bone scintigraphy and 18F-FDG PET/CT. / Coexistencia de metástasis óseas por cáncer gástrico y osteopoiquilia diagnosticadas mediante gammagrafía ósea y 18F-FDG PET/TC.

The coexistence of different bone diseases in the same patient involves a complex differential diagnosis. A patient is presented who was studied due to a renal mass that showed many sclerotic lesions in spine and limbs in conventional radiology and CT. These lesions were evaluated with 99mTC-HDP bone scintigraphy and 18F-FDG PET/CT, which helped to obtain the definitive pathological diagnosis of osteopoikilosis (OP) co-existing with gastric cancer bone metastases. Of the different imaging scans performed, bone scintigraphy was particularly relevant due to its ability to discriminate between benign and metastatic bone disease.

[Nuclear medicine and radiopharmaceuticals]. / Medicina nuclear y radiofármacos.

Nuclear Medicine is a medical specialty that allows modern diagnostics and treatments using radiopharmaceuticals original radiotracers (drugs linked to a radioactive isotope). In Europe, radiopharmaceuticals are considered a special group of drugs and thus their preparation and use are regulated by a set of policies that have been adopted by individual member countries. The radiopharmaceuticals used in diagnostic examinations are administered in very small doses. So, in general, they have no pharmacological action, side effects or serious adverse reactions. The biggest problem associated with their use are the alterations in their biodistribution that may cause diagnostic errors. Nuclear Medicine is growing considerably influenced by the appearance and development of new radiopharmaceuticals in both the diagnostic and therapeutic fields and primarily to the impact of new multimodality imaging techniques (SPECT-CT, PET-CT, PET-MRI, etc.). It's mandatory to know the limitations of these techniques, distribution and eventual physiological alterations of radiopharmaceuticals, contraindications and adverse reactions of radiological contrasts, and the possible interference of both.

Medicina nuclear y radiofármacos / Nuclear medicine and radiopharmaceuticals

La medicina nuclear es una moderna especialidad médica que permite realizar diagnósticos y tratamientos mediante la utilización de radiofármacos o radiotrazadores (fármacos unidos a un isótopo radioactivo). En Europa los radiofármacos se consideran un grupo especial de medicamentos y, por tanto, su preparación y su uso están regulados por un conjunto de directivas que han sido adoptadas por los distintos países miembros. Los radiofármacos que se emplean en las exploraciones diagnósticas se administran en dosis muy pequeñas por lo que, en general, no tienen ninguna acción farmacológica, ni efectos secundarios, ni reacciones adversas graves. El mayor problema asociado a su utilización son las alteraciones de su biodistribución, lo cual puede condicionar errores diagnósticos. La medicina nuclear está experimentando un notable crecimiento condicionado por la aparición y desarrollo de nuevos radiofármacos, tanto en el campo diagnóstico como en el terapéutico, y fundamentalmente por el impacto de las nuevas técnicas de imagen multimodalidad (SPECT-TC, PET-TC, PET-RM, etc.). Es necesario conocer las limitaciones de estas técnicas, la distribución fisiológica y las posibles alteraciones de los radiofármacos, las contraindicaciones y las reacciones adversas de los contrastes radiológicos, así como la posible interferencia de ambos (AU)

Nuclear Medicine is a medical specialty that allows modern diagnostics and treatments using radiopharmaceuticals original radiotracers (drugs linked to a radioactive isotope). In Europe, radiopharmaceuticals are considered a special group of drugs and thus their preparation and use are regulated by a set of policies that have been adopted by individual member countries. The radiopharmaceuticals used in diagnostic examinations are administered in very small doses. So, in general, they have no pharmacological action, side effects or serious adverse reactions. The biggest problem associated with their use are the alterations in their biodistribution that may cause diagnostic errors. Nuclear Medicine is growing considerably influenced by the appearance and development of new radiopharmaceuticals in both the diagnostic and therapeutic fields and primarily to the impact of new multimodality imaging techniques (SPECT-CT, PET-CT, PET-MRI, etc.). It's mandatory to know the limitations of these techniques, distribution and eventual physiological alterations of radiopharmaceuticals, contraindications and adverse reactions of radiological contrasts, and the possible interference of both (AU)

[The clinical relevance of FDG-PET imaging in severe traumatic brain injuries]. / Relevancia clínica de la FDG-PET en los traumatismos craneoencefálicos graves.

AIM: To evaluate the usefulness of positron emission tomography (PET) as a predictor of long-term disability after a severe traumatic brain injury (TBI). PATIENTS AND METHODS: Fifty-six patients who had sustained a severe TBI were assessed with a broad battery of cognitive and functional scales at baseline and 6-months after inclusion in a multidisciplinary rehabilitation program. All patients underwent a FDG-PET at baseline. A physician blind to clinical data performed a semiquantitative analysis (normal vs altered) of functional neuroimaging (PET), including four cortical and three subcortical areas. The total number of lesions (cortical, subcortical and total) was correlated to the intensity of the TBI and to clinical data at admission and at follow-up. RESULTS: All patients showed changes in cerebral metabolism, being the thalamus the area most frequently affected. The degree of cerebral hypometabolism showed a significant correlation with TBI severity, functional disability, global outcome and cognitive impairment not only at baseline but also at follow-up. CONCLUSIONS: According to our results, FDG-PET may be a useful tool when studying brain dysfunction after severe TBI. FDG-PET findings correlate with the TBI severity, and with the level of patients' disability, as well as with the degree of memory and intelligence impairment. However, clinical variables related to the severity of the TBI, still are the best predictors of functional outcome after TBI.

Relevancia clínica de la FDG-PET en los traumatismos craneoencefálicos graves / The clinical relevance of FDG-PET imaging in severe traumatic brain injuries

Resumen. Objetivo. Demostrar la utilidad de la tomografía por emisión de positrones (PET) como predictor de la discapacidad a largo plazo tras un traumatismo craneoencefálico (TCE). Pacientes y métodos. Se evaluó neuropsicológica y funcionalmente a 56 pacientes que habían sufrido un TCE grave al inicio y aproximadamente seis meses después de su inclusión en un programa de rehabilitación multidisciplinar. A todos los pacientes se les realizó una tomografía por emisión de positrones con fluordeoxiglucosa al inicio del tratamiento. De forma ciega, se determinó la presencia o ausencia de alteraciones en cuatro áreas corticales y tres subcorticales, y se determinaron tres índices cualitativos de metabolismo cerebral (cortical, subcortical y total). Los índices de metabolismo se correlacionaron con las variables relacionadas con la gravedad del traumatismo, y con la situación cognitiva y funcional de los pacientes en el momento de realizar la PET y al finalizar el programa de rehabilitación. Resultados. Todos los pacientes mostraron alteraciones en el metabolismo cerebral, y el tálamo fue el área más frecuentemente afectada. La intensidad del hipometabolismo cerebral se correlacionó significativamente con la gravedad del TCE y con la alteración cognitiva y funcional tanto al inicio como al final del tratamiento. Conclusiones. Las técnicas de neuroimagen funcional presentan una excelente sensibilidad para detectar alteraciones tras un TCE, además de ofrecer una buena correlación anatomoclínica. No obstante, las variables relacionadas con la gravedad del TCE, siguen siendo las mejores predictoras de la discapacidad resultante tras un TCE (AU)

Summary. Aim. To evaluate the usefulness of positron emission tomography (PET) as a predictor of long-term disability after a severe traumatic brain injury (TBI). Patients and methods. Fifty-six patients who had sustained a severe TBI were assessed with a broad battery of cognitive and functional scales at baseline and 6-months after inclusion in a multidisciplinary rehabilitation program. All patients underwent a FDG-PET at baseline. A physician blind to clinical data performed a semiquantitative analysis (normal vs altered) of functional neuroimaging (PET), including four cortical and three subcortical areas. The total number of lesions (cortical, subcortical and total) was correlated to the intensity of the TBI and to clinical data at admission and at follow-up. Results. All patients showed changes in cerebral metabolism, being the thalamus the area most frequently affected. The degree of cerebral hypometabolism showed a significant correlation with TBI severity, functional disability, global outcome and cognitive impairment not only at baseline but also at follow-up. Conclusions. According to our results, FDG-PET may be a useful tool when studying brain dysfunction after severe TBI. FDG-PET findings correlate with the TBI severity, and with the level of patients’ disability, as well as with the degree of memory and intelligence impairment. However, clinical variables related to the severity of the TBI, still are the best predictors of functional outcome after TBI (AU)

Osteosarcoma de fémur con metástasis peritoneal osificada / No disponible

No disponible

[Contribution of a portable hand-held miniature gamma camera in surgical treatment of primary hyperparathyroidism]. / Aportación de una minigammacámara portátil en el tratamiento quirúrgico del hiperparatiroidismo primario.

Primary hyperparathyroidism diagnosis and radioguided surgery by (99m)Tc-MIBI scintigraphy have become more generalized during recent years. The recent creation of a new portable hand-held miniature gamma camera opens new perspectives for this technique. We present a preliminary study of three patients with primary hyperparathyroidism in whom intraoperative scintigraphy with portable hand-held miniature gamma camera has been shown to be useful.

Aportación de una minigammacámara portátil en el tratamiento quirúrgico del hiperparatiroidismo primario / Contribution of a portable hand-held miniature gamma camera in surgical treatment of primary hyperparathyroidism

En los últimos años se ha generalizado el uso de la gammagrafía paratiroidea con 99mTc-MIBI para el diagnóstico preoperatorio e intraoperatorio del hiperparatiroidismo primario. La aparición de un nuevo modelo de minigammacámara portátil (MGP) abre nuevas perspectivas en el campo de la detección intraoperatoria. Presentamos un estudio preliminar de tres pacientes con hiperparatiroidismo primario en el que se demuestra la utilidad del empleo de la MGP

Primary hyperparathyroidism diagnosis and radioguided surgery by 99mTc-MIBI scintigraphy have become more generalized during recent years. The recent creation of a new portable hand-held miniature gamma camera opens new perspectives for this technique. We present a preliminary study of three patients with primary hyperparathyroidism in whom intraoperative scintigraphy with portable hand-held miniature gamma camera has been shown to be useful (AU)

Determinación del factor de calibración para el samario-153 en el activímetro de dosis CRC®-35R / Determination of dose calibrator setting of the capintec CRC®-35R for samarium-153

Determination of dose calibrator setting of the capintec CRC®-35R for samarium-153 Objetivo. Determinar el factor de calibración del activímetro para el radionucleido samario-153 (153Sm) y estudiar la influencia de la geometría en la medida de la actividad, de forma que se pueda determinar con exactitud la actividad administrada al paciente.Material y métodos. El factor de calibración del actinímetro para el 153Sm se determinó a partir del valor medio de la respuesta del detector en un canal de factor de calibración conocido, utilizando fuentes de 153Sm de uso clínico. El factor de corrección según geometría se calculó a partir del valor de actividad real indicada por el fabricante y las medidas de actividad realizadas en vial y jeringa. Resultados. El factor de calibración obtenido es de 239 ± 4. El factor de corrección que tiene en cuenta la geometría es de 0,87 ± 0,07. La actividad medida en jeringa es un 18 % superior a la medida en vial. Conclusiones. El método empleado permite medir correctamente la actividad de 153Sm, tanto en vial como en jeringa para dosificar con exactitud la actividad de Samario [153Sm] lexidronam administrada al paciente

Objetive. The aim of this work is to determine the calibration factor for Sm-153 and evaluate the influenceof the geometry in the activity measurements in order to administer accurately the activity to the patient.Methods. The calibration factor for Sm-153 was determinated using the Sm-153 sources commonly used in clinical practice and the calibrator response in a known calibration setting. The geometry correction factor for the vial and the plastic syringe was calculated using the real activity indicated by the manufacturer and the activity measured in the vial and in the plastic syringe.Results. The calibration factor obtained is 239 ± 4 and the correction factor which takes in consideration the geometry is 0,87 ± 0,07. The activity measured in the syringe is eighteen percent higher to activity measured in the vial. Conclusion. This method allows to measure accurately the activity of Sm-153 in vial and syringe applying this geometry correction factor to determine accurately the activity administered to the patient (AU)

[Determination of dose calibrator setting of the capintec CRC-35R for samarium-153]. / Determinación del factor de calibración para el samario-153 en el activímetro de dosis CRC-35R.

OBJECTIVE: The aim of this work is to determine the calibration factor for Sm-153 and evaluate the influence of the geometry in the activity measurements in order to administer accurately the activity to the patient. METHODS: The calibration factor for Sm-153 was determinated using the Sm-153 sources commonly used in clinical practice and the calibrator response in a known calibration setting. The geometry correction factor for the vial and the plastic syringe was calculated using the real activity indicated by the manufacturer and the activity measured in the vial and in the plastic syringe. RESULTS: The calibration factor obtained is 239 +/- 4 and the correction factor which takes in consideration the geometry is 0,87 +/- 0,07. The activity measured in the syringe is eighteen percent higher to activity measured in the vial. CONCLUSION: This method allows to measure accurately the activity of Sm-153 in vial and syringe applying this geometry correction factor to determine accurately the activity administered to the patient.